Clinical Trials

20 trials
RecentStart dateEnrollment
Phase 1 × Irinotecan × Sarcoma × Clear all
NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

National Cancer Institute (NCI)

Phase 1 Completed
41 enrolled
BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00101270 2013-06-05

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
CNSDermatologicGastrointestinalGenitourinaryHead & NeckLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Colonic Neoplasms, Medulloblastoma, Melanoma, Nasopharyngeal Neoplasms, Wilms Tumor, Neuroblastoma, Recurrence, Osteosarcoma, Lymphoma, Large B-Cell, Diffuse, Neuroectodermal Tumors, Primitive, Peripheral, Optic Nerve Glioma, Dendritic Cell Sarcoma, Interdigitating